Profiling of T- and B-cell receptor repertoires in an individual has led to a vast repository of information on acquired immunity against various microorganisms.
Next-generation Immune Repertoire Sequencing Market: Introduction
Profiling of T- and B-cell receptor repertoires in an individual has led to a vast repository of information on acquired immunity against various microorganisms. Next-generation immune repertoire sequencing has allowed researchers to make sophisticated immuno-bioinformatics analyses. It has generated interest among the research community and biopharmaceutical industries in the clinical development of antibody engineering, vaccine design, and cellular immunotherapy.
Read Report Overview - https://www.transparencymarketresearch.com/next-generation-immune-repertoire-sequencing-market.html
Rise in applications of nutritional and intestinal immunology drives the rapid evolution of next-generation immune repertoire sequencing. The innovative technology has provided unprecedented insights into host-microbiome immune homeostasis, and along with single-cell transcriptomics presents significant opportunities in the life sciences industries across the world.
Immune repertoire sequencing is utilized in biomarker discovery to enhance the success rate and cost-effectiveness of rational drug development. For instance, in November 2017, the Center for Commercialization of Cancer Immunotherapy (C3i) started offering T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit in Canada. Rise in demand for personalized medicine is anticipated to support the immune repertoire sequencing market growth, as personalized medicine uses an individual’s genetic profile to guide decisions made with regard to the prevention, diagnosis, and treatment of diseases.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=58701
Key Drivers, Restraints, and Opportunities of Global Next-generation Immune Repertoire Sequencing Market
Rise in need of expanding the understanding of key processes in systems immunology is a key factor driving the demand for next-generation immune repertoire sequencing. Increase in applications of TCR repertoire sequencing in clinical settings is one of the key aspects in improving immune repertoire sequencing.
Over the past several years, this has generated a groundswell of interest in this high-throughput sequencing in realms of nutritional and intestinal immunology. Its potential application in gaining insight into lymphocyte diversity has gained some traction, catalyzing the market’s growth. For example, next-generation immune repertoire sequencing has potential in detecting minimal residual disease in lymphoid malignancies post treatment. This helps in evaluating the effectiveness of vaccination.
Furthermore, increase in the role of next-generation immune repertoire sequencing for personalized immune modulation is a key trend in the global next-generation immune repertoire sequencing market. Rise in need of better anti-cancer treatment will galvanize research into immune therapy and vaccine development with the help of next-generation immune repertoire sequencing. New avenues in intestinal immunology will pave the way for new, exciting products in the market.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=58701
North America to Capture Major Share of Global Next-Generation Immune Repertoire Sequencing Market
Developed regions such as North America and Europe are expected to make significant progress and likely to account for substantial share of the global next-generation immune repertoire sequencing market in terms of revenue. The market in North America is driven by growing traction that immunotherapy has gained in the treatment of cancer and infectious diseases. Developments in Europe are expected to be driven by sizeable funding in biomedical research and rise in research in genomic and autoimmune disease.
North America is anticipated to dominate the global market during the forecast period due to the presence of key industry players in the region (including Thermo Fisher Scientific, Illumina Inc., Pacific Biosciences, and CD Genomics). These players are increasingly focusing on development of novel technologies for immune repertoire sequencing. For example, in 2017, 10x Genomics Inc., a U.S.-based company, added B-Cell and 5’Unbiased Enrichment Kit to its chromium immune repertoire profiling solution or immune repertoire sequencing.
The market in Europe is likely to grow at a rapid pace in the next few years. The market in the region is anticipated to gain momentum during the forecast period, due to increase in funding by the government bodies to assist international innovative projects and marketable innovative products, processes, and services, in order to cater to unmet medical needs. In July 2018, Eurostars (a joint program between EUREKA and the European Commission) granted US$ 495,000 to OSE Immunotherapeutic SA’s project titled: ‘Treatment Response Monitoring for Cancer Immunotherapies utilizing Immune Repertoire Analysis’.
Pre Book Next-generation Immune Repertoire Sequencing Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=58701<ype=S
Key Players Operating in Global Next-generation Immune Repertoire Sequencing Market
The presence of several prominent players in developed regions has raised the intensity of competition in the global market in the past few years. These players make significant investments in research & development of immuno-bioinformatics analyses using next-generation immune repertoire sequencing.
Major players operating in the global next-generation immune repertoire sequencing market are:
- Adaptive Biotechnologies
- Atreca, Inc.
- CD Genomics
- Pacific Biosciences
- Juno Therapeutics
- Roche Holding AG
- ArcherDX, Inc.
- Illumina, Inc.
- Abvitro (Now Juno Therapeutics)
- Agilent Technologies
- Bgi
- Irepertoire, Inc.
- Oxford Nanopore Technologies, Ltd.
- Qiagen N.V.
- Takara Bio, Inc.
- Thermo Fisher Scientific
- Others
Browse more Reports by Transparency Market Research:
Prostate Cancer Diagnostics Market: Increased prevalence of prostate cancer, growing awareness among people, rising treatment demand, and availability of new treatments are key drivers boosting the prostate cancer diagnostics market.
Pharma-grade Magnesium Trisilicate Market: Asia Pacific is anticipated to account for a considerable share of the global pharma-grade magnesium trisilicate market from 2020 to 2030. The market in the region is projected to expand at a rapid pace during the forecast period. Expansion of the market in the region is attributed due to a surge in number of entrants of new suppliers and manufacturers.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/